Centre Léon Bérard Lyon and Université Claude Bernard Lyon I, Lyon, France; Equipe 17 INSERM CRCL, LYRIC (INCA-DGOS 4664), NetSARC, RREPS, and EuroSARC (FP7-278742), Lyon, France; European Organisation for Research and Treatment of Cancer, Lyon, France.
Institut Bergonie, Bordeaux, France.
Lancet Oncol. 2016 Feb;17(2):e62-e69. doi: 10.1016/S1470-2045(15)00388-5.
Rare cancers are defined by an incidence of less than six per 100,000 people per year. They represent roughly 20% of all human cancers and are associated with worse survival than are so-called frequent tumours, because of delays to accurate diagnosis, inadequate treatments, and fewer opportunities to participate in clinical trials (because of a paucity of dedicated trials from both academic and industrial sponsors). In this Series paper, we discuss how these challenges can be addressed by research consortia and suggest the integration of these consortia with reference networks, which gather multidisciplinary expert centres, for management of rare tumours.
罕见癌症的定义是每年每 10 万人中发病率低于 6 人。它们约占所有人类癌症的 20%，与所谓的常见肿瘤相比，生存率更差，因为存在诊断不准确、治疗不足以及参与临床试验机会较少的情况（这是由于学术和工业赞助商缺乏专门的试验）。在本系列论文中，我们讨论了研究联盟如何应对这些挑战，并建议将这些联盟与参考网络（汇集多学科专家中心）整合，以管理罕见肿瘤。
